Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.

about

Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer.Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

P2860

Q37710928-2168C59B-1E09-4DDC-839F-0E4AE5BE4A70 Q57165997-7E87F622-5938-4DCF-8DD5-1FBD0C329A3B

P2860

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.

Item

http://www.wikidata.org/entity/Q39222023

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Predictors of early androgen d ...... e cancer with bone metastases.

@en

Predictors of early androgen d ...... e cancer with bone metastases.

@nl

type

Item

label

Predictors of early androgen d ...... e cancer with bone metastases.

@en

Predictors of early androgen d ...... e cancer with bone metastases.

@nl

prefLabel

Predictors of early androgen d ...... e cancer with bone metastases.

@en

Predictors of early androgen d ...... e cancer with bone metastases.

@nl

P1476

Predictors of early androgen d ...... e cancer with bone metastases.

@en

P2093

Anders Berglund

http://www.w3.org/2001/XMLSchema#string

Eberhard Varenhorst

http://www.w3.org/2001/XMLSchema#string

Gabriel Sandblom

http://www.w3.org/2001/XMLSchema#string

Per Olov Hedlund

http://www.w3.org/2001/XMLSchema#string

Rami Klaff

http://www.w3.org/2001/XMLSchema#string

Scandinavian Prostate Cancer Group (SPCG) Trial No. 5

http://www.w3.org/2001/XMLSchema#string

P2860

Integrative clinical genomics of advanced prostate cancer.

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

The development of androgen-independent prostate cancer

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Neuroendocrine differentiation in prostatic carcinoma.

Hormonal therapy for stage D cancer of the prostate

Treatment of stage IV carcinoma of the prostate.

Copy number alteration burden predicts prostate cancer relapse

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

P304

407-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.594

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26765317

http://www.w3.org/2001/XMLSchema#string

P932

4799954

http://www.w3.org/2001/XMLSchema#string

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.

about

P2860

P2860

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932